Lorrain Daniel S., Chief Scientific Officer of Contineum Therapeutics, Inc. ($CTNM), sold shares on the open market 10 times over the past year, totaling about $358,000. His most recent sale occurred on March 2, 2026. These sales rank 7,181st among 11,678 individual insiders in our database, where the average is $8.6 million across 6.4 transactions per insider. Lorrain Daniel S. made no open market purchases in the last 365 days.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 2, 2026 | Contineum Therapeutics, Inc. | $CTNM | Lorrain Daniel S. | Chief Scientific Officer | S | Class A Common Stock | 4170 | $15.01 | 158,724.0000 | 28,115,548 | 2.56% | 0.01% |
| Feb. 25, 2026 | Contineum Therapeutics, Inc. | $CTNM | Lorrain Daniel S. | Chief Scientific Officer | M | Stock Option (right to buy) | 3824 | $0.00 | 67,306.0000 | 28,115,548 | 5.38% | 0.01% |
| Feb. 24, 2026 | Contineum Therapeutics, Inc. | $CTNM | Lorrain Daniel S. | Chief Scientific Officer | M | Stock Option (right to buy) | 4300 | $0.00 | 71,130.0000 | 28,115,548 | 5.70% | 0.02% |
| Feb. 25, 2026 | Contineum Therapeutics, Inc. | $CTNM | Lorrain Daniel S. | Chief Scientific Officer | S | Class A Common Stock | 3824 | $16.01 | 162,894.0000 | 28,115,548 | 2.29% | 0.01% |
| Feb. 25, 2026 | Contineum Therapeutics, Inc. | $CTNM | Lorrain Daniel S. | Chief Scientific Officer | M | Class A Common Stock | 3824 | $1.01 | 166,718.0000 | 28,115,548 | 2.35% | 0.01% |
| Feb. 24, 2026 | Contineum Therapeutics, Inc. | $CTNM | Lorrain Daniel S. | Chief Scientific Officer | S | Class A Common Stock | 4300 | $16.03 | 162,894.0000 | 28,115,548 | 2.57% | 0.02% |
| Feb. 24, 2026 | Contineum Therapeutics, Inc. | $CTNM | Lorrain Daniel S. | Chief Scientific Officer | M | Class A Common Stock | 4300 | $1.01 | 167,194.0000 | 28,115,548 | 2.64% | 0.02% |
| Feb. 19, 2026 | Contineum Therapeutics, Inc. | $CTNM | Lorrain Daniel S. | Chief Scientific Officer | M | Stock Option (right to buy) | 100 | $0.00 | 75,430.0000 | 28,115,548 | 0.13% | 0.00% |
| Feb. 19, 2026 | Contineum Therapeutics, Inc. | $CTNM | Lorrain Daniel S. | Chief Scientific Officer | S | Class A Common Stock | 100 | $16.00 | 162,894.0000 | 28,115,548 | 0.06% | 0.00% |
| Feb. 19, 2026 | Contineum Therapeutics, Inc. | $CTNM | Lorrain Daniel S. | Chief Scientific Officer | M | Class A Common Stock | 100 | $1.01 | 162,994.0000 | 28,115,548 | 0.06% | 0.00% |
| Feb. 11, 2026 | Contineum Therapeutics, Inc. | $CTNM | Lorrain Daniel S. | Chief Scientific Officer | M | Class A Common Stock | 400 | $1.01 | 163,294.0000 | 28,115,548 | 0.25% | 0.00% |
| Feb. 11, 2026 | Contineum Therapeutics, Inc. | $CTNM | Lorrain Daniel S. | Chief Scientific Officer | M | Stock Option (right to buy) | 400 | $0.00 | 75,530.0000 | 28,115,548 | 0.53% | 0.00% |
| Feb. 11, 2026 | Contineum Therapeutics, Inc. | $CTNM | Lorrain Daniel S. | Chief Scientific Officer | S | Class A Common Stock | 400 | $16.00 | 162,894.0000 | 28,115,548 | 0.24% | 0.00% |
| Feb. 3, 2026 | Contineum Therapeutics, Inc. | $CTNM | Lorrain Daniel S. | Chief Scientific Officer | S | Class A Common Stock | 1170 | $15.25 | 162,894.0000 | 28,115,548 | 0.71% | 0.00% |
| Feb. 3, 2026 | Contineum Therapeutics, Inc. | $CTNM | Lorrain Daniel S. | Chief Scientific Officer | S | Class A Common Stock | 3000 | $14.82 | 164,064.0000 | 28,115,548 | 1.80% | 0.01% |
| Jan. 30, 2026 | Contineum Therapeutics, Inc. | $CTNM | Lorrain Daniel S. | Chief Scientific Officer | A | Stock Option (right to buy) | 6500 | $0.00 | 166,500.0000 | 28,115,548 | 4.06% | 0.02% |
| Jan. 30, 2026 | Contineum Therapeutics, Inc. | $CTNM | Lorrain Daniel S. | Chief Scientific Officer | A | Stock Option (right to buy) | 160000 | $0.00 | 166,500.0000 | 28,115,548 | 2461.54% | 0.57% |
| Jan. 5, 2026 | Contineum Therapeutics, Inc. | $CTNM | Lorrain Daniel S. | Chief Scientific Officer | S | Class A Common Stock | 500 | $11.13 | 167,064.0000 | 28,115,548 | 0.30% | 0.00% |
| Jan. 5, 2026 | Contineum Therapeutics, Inc. | $CTNM | Lorrain Daniel S. | Chief Scientific Officer | S | Class A Common Stock | 3670 | $10.35 | 167,564.0000 | 28,115,548 | 2.14% | 0.01% |
| Dec. 23, 2025 | Contineum Therapeutics, Inc. | $CTNM | Lorrain Daniel S. | Chief Scientific Officer | S | Class A Common Stock | 4170 | $12.23 | 171,234.0000 | 28,115,548 | 2.38% | 0.01% |
| Jan. 31, 2025 | Contineum Therapeutics, Inc. | $CTNM | Lorrain Daniel S. | Chief Scientific Officer | A | Stock Option (right to buy) | 110000 | $0.00 | 113,700.0000 | 19,352,859 | 2972.97% | 0.57% |
| Jan. 31, 2025 | Contineum Therapeutics, Inc. | $CTNM | Lorrain Daniel S. | Chief Scientific Officer | A | Stock Option (right to buy) | 3700 | $0.00 | 113,700.0000 | 19,352,859 | 3.36% | 0.02% |
| Nov. 25, 2024 | Contineum Therapeutics, Inc. | $CTNM | Lorrain Daniel S. | Chief Scientific Officer | S | Class A Common Stock | 1010 | $16.02 | 172,460.0000 | 25,730,014 | 0.58% | 0.00% |
| Nov. 18, 2024 | Contineum Therapeutics, Inc. | $CTNM | Lorrain Daniel S. | Chief Scientific Officer | S | Class A Common Stock | 99 | $17.05 | 173,470.0000 | 25,730,014 | 0.06% | 0.00% |
| Nov. 18, 2024 | Contineum Therapeutics, Inc. | $CTNM | Lorrain Daniel S. | Chief Scientific Officer | S | Class A Common Stock | 6091 | $16.37 | 173,569.0000 | 25,730,014 | 3.39% | 0.02% |
| May 24, 2024 | Contineum Therapeutics, Inc. | $CTNM | Lorrain Daniel S. | Chief Scientific Officer | A | Stock Option (right to buy) | 100000 | $0.00 | 103,700.0000 | 2,308,972 | 2702.70% | 4.33% |
| May 24, 2024 | Contineum Therapeutics, Inc. | $CTNM | Lorrain Daniel S. | Chief Scientific Officer | A | Stock Option (right to buy) | 3700 | $0.00 | 103,700.0000 | 2,308,972 | 3.70% | 0.16% |